《新股表现》中国鹏飞(03348.HK)暗盘收报1.59元 高上市价0.6%
根据辉立交易平台显示,明天挂牌的中国鹏飞(03348.HK)暗盘低开近18%报1.3元,最低见1.2元获承接,掉头高见1.7元,收报1.59元,较上市价1.58元,高0.6%或1仙。成交1,040万股,涉资1,700万元。
鹏飞是中国及全球市场领先的回转窑、粉磨设备及相关设备制造商,在业内经营逾20年。是次上市共发售1.25亿股,其中10%公开发售获近27倍超购,已启动回拨机制占比增至30%,认购一手中签率50%;股份以招股范围(1.05-1.58元)上限定价,料集资净额1.533亿元,其中78.7%将用作投资一个生产具备最新焙烧及热解技术回转窑项目。上市保荐人安信国际。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.